American Journal of Cardiology
Volume 102, Issue 3 , Pages 368-369 , 1 August 2008

Enhanced Hype

  • David G. Harrison, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia
    • Atlanta Veterans Administration Hospital, Decatur, Georgia.
    • Corresponding Author InformationCorresponding author: Tel: 404-727-3710; fax: 404-727-3585.
    • ,
  • W. Virgil Brown, MD

      Affiliations

    • Division of Endocrinology/Metabolism, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia
    • Atlanta Veterans Administration Hospital, Decatur, Georgia.
    • ,
  • Paolo Raggi, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia
    • Department of Radiology, Emory University School of Medicine, Atlanta, Georgia
    • Atlanta Veterans Administration Hospital, Decatur, Georgia.

Received 4 May 2008 ,Revised 16 May 2008 ,Accepted 16 May 2008.

References 

  1. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431–1443
  2. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998;128:262–269
  3. Calabro P, Yeh ET. The pleiotropic effects of statins. Curr Opin Cardiol. 2005;20:541–546
  4. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, et al Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia (Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)). N Engl J Med. 1990;323:946–955
  5. The Lipid Research Clinics Coronary Primary Prevention Trial results (I. Reduction in incidence of coronary heart disease). JAMA. 1984;251:351–364
  6. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–1255
  7. Watts GF, Lewis B, Brunt JN, Lewis ES, Coltart DJ, Smith LD, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet. 1992;339:563–569
  8. Harrison DG, Armstrong ML, Freiman PC, Heistad DD. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest. 1987;80:1808–1811
  9. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106:1943–1948
  10. Salen G, von Bergmann K, Lutjohann D, Kwiterovich P, Kane J, Patel SB, et al. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation. 2004;109:966–971

PII: S0002-9149(08)00890-4

doi: 10.1016/j.amjcard.2008.05.017

American Journal of Cardiology
Volume 102, Issue 3 , Pages 368-369 , 1 August 2008

Article Tools